Alzamend Neuro, Inc., is pleased to announce that the US Food and Drug Administration has given the green light for its Phase I/IIA Trial Under Its Investigational New Drug Application for an Immunotherapy Vaccine (ALZN002) to Treat Mild to Moderate Dementia of the Alzheimer’s Type.
The FDA has issued a “Study May Proceed” letter, allowing Alzamend Neuro to move forward with its research and development of ALZN002.
Alzamend Neuro, Inc. made an unfortunate mistake when they mistakenly issued a release.
On April 3, 2023, at 08:50 AM Eastern Time, a new release was issued to replace the existing one. Get ready for the exciting update!